| Primary |
| Amyotrophic Lateral Sclerosis |
46.6% |
| Drug Use For Unknown Indication |
12.3% |
| Motor Neurone Disease |
8.2% |
| Spinal Muscular Atrophy |
5.1% |
| Constipation |
3.8% |
| Hypertension |
3.4% |
| Depression |
2.7% |
| Insomnia |
2.1% |
| Pain |
2.1% |
| Anxiety |
1.4% |
| Deep Vein Thrombosis |
1.4% |
| Diabetes Mellitus |
1.4% |
| Gastritis |
1.4% |
| Nervous System Disorder |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| Pyramidal Tract Syndrome |
1.4% |
| Cardiovascular Event Prophylaxis |
1.0% |
| Cerebral Infarction |
1.0% |
| Eating Disorder |
1.0% |
| Pneumonia |
1.0% |
|
| Death |
30.8% |
| Pyrexia |
9.1% |
| Respiratory Failure |
7.0% |
| Pneumonia |
5.6% |
| Disease Progression |
4.9% |
| Myocardial Infarction |
4.2% |
| Interstitial Lung Disease |
3.5% |
| Pneumonia Aspiration |
3.5% |
| Pulmonary Embolism |
3.5% |
| Agranulocytosis |
2.8% |
| Dysphagia |
2.8% |
| Dyspnoea |
2.8% |
| Melaena |
2.8% |
| Motor Neurone Disease |
2.8% |
| Tachycardia |
2.8% |
| Weight Decreased |
2.8% |
| Hepatitis Fulminant |
2.1% |
| Hypokalaemia |
2.1% |
| Increased Upper Airway Secretion |
2.1% |
| International Normalised Ratio Increased |
2.1% |
|
| Secondary |
| Amyotrophic Lateral Sclerosis |
36.8% |
| Pyramidal Tract Syndrome |
9.2% |
| Drug Use For Unknown Indication |
8.0% |
| Depression |
4.6% |
| Gastritis |
4.6% |
| Product Used For Unknown Indication |
4.6% |
| Urinary Tract Infection |
4.6% |
| Hypertension |
3.4% |
| Pneumonia |
3.4% |
| Atrial Flutter |
2.3% |
| Blindness |
2.3% |
| Bulbar Palsy |
2.3% |
| Constipation |
2.3% |
| Muscle Spasticity |
2.3% |
| Premedication |
2.3% |
| Stem Cell Transplant |
2.3% |
| Anxiety |
1.1% |
| Asthma |
1.1% |
| Cerebral Infarction |
1.1% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
1.1% |
|
| Pyrexia |
11.8% |
| Melaena |
8.8% |
| Tardive Dyskinesia |
8.8% |
| Blood Pressure Decreased |
5.9% |
| Diarrhoea |
5.9% |
| Hepatic Function Abnormal |
5.9% |
| Pneumonia Aspiration |
5.9% |
| Shock |
5.9% |
| Talipes |
5.9% |
| Urinary Retention |
5.9% |
| Aspartate Aminotransferase Increased |
2.9% |
| Deep Vein Thrombosis |
2.9% |
| Fatigue |
2.9% |
| Infection |
2.9% |
| Liver Disorder |
2.9% |
| Off Label Use |
2.9% |
| Skin Exfoliation |
2.9% |
| Somnolence |
2.9% |
| Syncope |
2.9% |
| Therapeutic Response Unexpected |
2.9% |
|
| Concomitant |
| Amyotrophic Lateral Sclerosis |
24.6% |
| Product Used For Unknown Indication |
14.0% |
| Hypertension |
11.5% |
| Hepatitis B |
9.7% |
| Pain |
7.5% |
| Drug Use For Unknown Indication |
5.3% |
| Multiple Sclerosis |
4.7% |
| Depression |
3.1% |
| Constipation |
2.8% |
| Dyslipidaemia |
2.5% |
| Atrial Fibrillation |
2.2% |
| Muscle Spasms |
1.9% |
| Salivary Hypersecretion |
1.6% |
| Anxiety |
1.2% |
| Benign Prostatic Hyperplasia |
1.2% |
| Cerebral Infarction |
1.2% |
| Diuretic Therapy |
1.2% |
| Muscle Spasticity |
1.2% |
| Osteoporosis |
1.2% |
| Peritoneal Dialysis |
1.2% |
|
| Blood Alkaline Phosphatase Increased |
8.6% |
| Amyotrophic Lateral Sclerosis |
6.9% |
| Chest Pain |
6.9% |
| Malaise |
6.9% |
| Multiple Fractures |
6.9% |
| Respiratory Failure |
6.9% |
| Death |
5.2% |
| Urinary Tract Infection |
5.2% |
| Urticaria |
5.2% |
| Vomiting |
5.2% |
| Weight Decreased |
5.2% |
| Blood Cholesterol |
3.4% |
| Dysarthria |
3.4% |
| Motor Neurone Disease |
3.4% |
| Muscular Weakness |
3.4% |
| Osteomalacia |
3.4% |
| Oxygen Saturation Decreased |
3.4% |
| Pain In Extremity |
3.4% |
| Paraneoplastic Syndrome |
3.4% |
| Peritonitis |
3.4% |
|
| Interacting |
| Depression |
55.6% |
| Amyotrophic Lateral Sclerosis |
16.7% |
| Anxiety Disorder |
11.1% |
| Essential Hypertension |
5.6% |
| Insomnia |
5.6% |
| Motor Neurone Disease |
5.6% |
|
| Hypotension |
75.0% |
| Toxicity To Various Agents |
25.0% |
|
